Fox Lake Towing and Recovery

Teaming with Massachusetts General Hospital and others, J&J’s Veridex is developing a novel method of isolating cancer cells from a patient’s bloodstream. If successful, the blood test could ultimately replace more invasive and painful ones such as biopsies.

Continue reading J&J Unit to Develop Blood Test to Find Cancer Cells

J&J Unit to Develop Blood Test to Find Cancer Cells originally appeared on DailyFinance on Mon, 03 Jan 2011 09:45:00.

Filed Under: Company News, Health Care, Johnson & Johnson

Prestigious management consulting firm McKinsey & Co. just published Value: The Four Cornerstones of Corporate Finance, a guide to help executives create shareholder value. Lead author Tim Koller shares his thoughts with DailyFinance about how the book might also help investors profit.

Continue reading McKinsey’s New Management Guide Also Offers ‘Value’ to Investors

McKinsey’s New Management Guide Also Offers ‘Value’ to Investors originally appeared on DailyFinance on Sun, 05 Dec 2010 08:00:00.

Filed Under: Investing, Investing Basics, Books

The conglomerate said Tuesday that it plans to invest more than $2 billion in China through 2012 in research and development, technology and financial services partnerships. The move marks GE’s “confidence in China’s long-term economic prospects.”

Continue reading General Electric to Invest $2 Billion in China

General Electric to Invest $2 Billion in China originally appeared on DailyFinance on Tue, 09 Nov 2010 08:42:00.

Filed Under: Company News, General Electric , Stocks in the News

Corporate America took a tightfisted approach to its future last year, leading to an overall 3.5% decline in research and development spending at major industry titans, the first such drop in over a decade, according to a Booz & Co. survey cited by The Wall Street Journal.

Continue reading R&D Spending Dipped in 2009 for the First Time in a Decade

R&D Spending Dipped in 2009 for the First Time in a Decade originally appeared on DailyFinance on Wed, 03 Nov 2010 11:29:00.

Filed Under: Company News, Technology, Economy, Microsoft, Apple

Swiss pharmaceutical company Novartis announced Tuesday that it had discontinued the development of two drugs — the hepatitis C treatment Zalbin, and antifungal agent Mycograb. The company will take impairment charges of approximately $590 million in third quarter of 2010.

Continue reading Novartis Discontinues Two Drug Development Programs

Novartis Discontinues Two Drug Development Programs originally appeared on DailyFinance on Tue, 05 Oct 2010 12:04:00.

Filed Under: Health Care, Novartis